Photodynamic therapy for subfoveal choroidal neovascularisation in various diseases among which age-related macular degeneration: An update

Medical Laser Application

Volumn 18, Issue 1, 2003, Pages 65-78

  Van den Bergh, Hubert ^a   Ballini, Jean Pierre ^a   Sickenberg, Michel ^b  

^a EPFL   (Switzerland)

^b NONE   (Switzerland)

Author keywords

Macular degeneration; Photodynamic therapy; Subfoveal choroidal neovascularisation; Verteporfin

Indexed keywords

COSTS; DISEASES; VISION;

SENSITIVITY LOSS;

PHOTODYNAMIC THERAPY;

BENZOPORPHYRIN DERIVATIVE; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 9; HYDROXYL RADICAL; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; VASCULOTROPIN;

CLINICAL TRIAL; DRUG SAFETY; HUMAN; LASER COAGULATION; PHOTODYNAMIC THERAPY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 0037397427     PISSN: 16151615     EISSN: None     Source Type: Journal    
DOI: 10.1078/1615-1615-00089     Document Type: Review

References (79)

1. AACSG: Anecortave Acetate as Monotherapy for the Treatment of Subfoveal Lesions in Patients with Exudative Agerelated Macular Degeneration (AMD): Interim (Month 6) Analysis of Clinical Safety and Efficacy, by The Anecortave Acetate Clinical Study Group (AACSG) (corresponding author: Slakter J.S.). Retina accepted (January 2003)
2. AISENBREY S, LAFAUT BA, SZURMAN P, GRISANTI S, LUKE C, KROTT R, THUMANN G, FRICKE J, NEUGEBAUER A, HILGERS RD, ESSER P, WALTER P, BARTZ-SCHMIDT KU: Macular translocation with 360 degrees retinotomy for exudative agerelated macular degeneration. Arch Ophthalmol 120: 451-459 (2002)
3. AMBATI BK, JOUSSEN AM, AMBATI J, MOROMIZATO Y, GUHA C, JAVAHERIAN K, GILLIES S, O'REILLY MS, ADAMIS AP: Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 120: 1063-1068 (2002)
4. AREDS: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: Age-Related Eye Disease Study Research Group: AREDS report no. 8. Arch Ophthalmol 119: 1417-1436 (2001)
5. ARMSTRONG D, SANTANGELO G, CONNOLE E: The distribution of peroxide regulating enzymes in the canine eye. Curr Eye Res 1: 225-242 (1981)
6. ATEBARA NH: Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol 134: 788-790 (2002)
7. AUER C, TAO TRAN V, HERBORT CP: Transpupillary thermotherapy for occult subfoveal neovessels in age-related macular degeneration: importance of patient pigmentation for the determination of laser settings. Klin Monatsbl Augenheilkd 219: 250-253 (2002)
8. AUGUSTIN AJ, DICK HB, OFFERMANN I, SCHMIDT-ERFURTH U: The significance of oxidative mechanisms in diseases of the retina. Klin Monatsbl Augenheilkd 219: 631-643 (2002)
9. BEN-SHABAT S, ITAGAKI Y, JOCKUSCH S, SPARROW JR, TURRO NJ, NAKANISHI K: Formation of a Nonaoxirane from A2E, a Lipofuscin Fluorophore related to Macular Degeneration, and Evidence of Singlet Oxygen Involvement. Angew Chem Int Ed Engl 41: 814-817 (2002)
10. BENEZRA D, GRIFFIN BW, MAFTZIR G, SHARIF NA, CLARK AF: Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. Invest Ophthalmol Vis Sci 38:1954-1962 (1997)
11. BONNETT R: Chemical Aspects of Photodynamic Therapy: 305. 1. Gordon and Breach Science Publishers, New York 2000
12. BOULTON M, ROZANOWSKA M, ROZANOWSKI B: Retinal photodamage. J Photochem Photobiol B 64: 144-161 (2001)
13. BRAUCHLE M, FUNK JO, KIND P, WERNER S: Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 271: 21793-21797 (1996)
14. CIULLA TA, DANIS RP, KLEIN SB, MALINOVSKY VE, SONI PS, PRATT LM, PUGH NO, MORPHIS JG, BLOCH C, CAMERON J: Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. Am J Ophthalmol 134: 905-906 (2002)
15. DANTAS MA, SLAKTER JS, NEGRAO S, FONSECA RA, KAGA T, YANNUZZI LA: Photodynamic therapy with verteporfin in mallatia leventinese. Ophthalmology 109: 296-301 (2002)
16. DE LA PAZ M, ANDERSON RE: Region and age-dependent variation in susceptibility of the human retina to lipid peroxidation. Invest Ophthalmol Vis Sci 33: 3497-3499 (1992)
17. DOUGHERTY TJ, GOMER CJ, HENDERSON BW, JORI G, KESSEL D, KORBELIK M, MOAN J, PENG Q: Photodynamic therapy. J Natl Cancer Inst 90: 889-905 (1998)
18. FARAH ME, COSTA RA, MUCCIOLI C, GUIA TA, BELFORT R, JR.: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 134: 137-139 (2002)
19. FERRARA N, BUNTING S: Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 5: 35-44 (1996)
20. GAILLARD ER, ATHERTON SJ, ELDRED G, DILLON J: Photophysical studies on human retinal lipofuscin. Photochem Photobiol 61: 448-453 (1995)
21. GREINER R-A: Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy. Seminars in Ophthalmology 16: 218-222 (2002)
22. HADEYAMA T, EBIHARA N, WATANABE Y, NAKAYASU K, KANAI A: Inhibitory effects of matrix metalloproteinase inhibitor on corneal neovascularization. Nippon Ganka Gakkai Zasshi 102: 270-275 (1998)
23. HAM WT, JR., MUELLER HA, RUFFOLO JJ, JR., MILLEN JE, CLEARY SF, GUERRY, RK, GUERRY D, 3rd: Basic mechanisms underlying the production of photochemical lesions in the mammalian retina. Curr Eye Res 3: 165-174 (1984)
24. JOUSSEN AM, GERMANN T, KIRCHHOF B: Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency. Graefes Arch Clin Exp Ophthalmol 237: 952-961 (1999)
25. KARACORLU M, KARACORLU S, OZDEMIR H, MAT C: Photodynamic therapy with verteporfin for choroidal neovascularization in patients with angioid streaks. Am J Ophthalmol 134: 360-366 (2002)
26. KIM KJ, LI B, WINER J, ARMANINI M, GILLETT N, PHILLIPS HS, FERRARA N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844 (1993)
27. KRZYSTOLIK MG, AFSHARI MA, ADAMIS AP, GAUDREAULT J, GRAGOUDAS ES, MICHAUD NA, LI W, CONNOLLY E, O'NEILL CA, MILLER JW: Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120: 338-346 (2002)
28. KUROKI M, VOEST EE, AMANO S, BEEREPOOT LV, TAKASHIMA S, TOLENTINO M, KIM RY, ROHAN RM, COLBY KA, YEO KT, ADAMIS AP: Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98: 1667-1675 (1996)
29. LADD BS, SOLOMON SD, BRESSLER NM, BRESSLER SB: Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy. Am J Ophthalmol 132: 659-667 (2001)
30. MADREPERLA SA: Choroidal hemangioma treated with photodynamic therapy using verteporfin. Arch Ophthalmol 119: 1606-1610 (2001)
31. MPSG: Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 109: 1220-1231 (1991)
32. MPSG: Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 111: 1200-1209 (1993)
33. MPSG: Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration. The influence of initial lesion size and initial visual acuity. Macular Photocoagulation Study Group. Arch Ophthalmol 112: 480-488 (1994)
34. NOELL WK: Possible mechanisms of photoreceptor damage by light in mammalian eyes. Vision Res 20: 1163-1171 (1980)
35. OLEINICK NL, MORRIS RL, BELICHENKO I: The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 1: 1-21 (2002)
36. PIERMAROCCHI S, LO GIUDICE G, SARTORE M, FRIEDE F, SEGATO T, PILOTTO E, MIDENA E: Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration. Am J Ophthalmol 133: 572-575 (2002)
37. POTTER MJ, SZABO SM, CHAN EY, MORRIS AH: Photodynamic therapy of a subretinal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis. Am J Ophthalmol 133: 149-151 (2002)
38. PULIAFITO C: Retinal Pharmacotherapy for Choroidal Neovascularisation A Paradigm Shift in Progress. Retinal Research Report Sept: 22-23 (2002)
39. QUARANTA M, MAUGET-FAYSSE M, COSCAS G: Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am J Ophthalmol 134: 277-280 (2002)
40. REICHEL E, BERROCAL AM, IP M, KROLL AJ, DESAI V, DUKER JS, PULIAFITO CA: Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 106: 1908-1914 (1999)
41. RENNO RZ, MILLER JW: Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. Adv Drug Deliv Rev 52: 63-78 (2001)
42. ROBERTSON DM: Photodynamic therapy for choroidal hemangioma associated with serous retinal detachment. Arch Ophthalmol 120: 1155-1161 (2002)
43. ROZANOWSKA M, JARVIS-EVANS J, KORYTOWSKI W, BOULTON ME, BURKE JM, SARNA T: Blue light-induced reactivity of retinal age pigment. In vitro generation of oxygen-reactive species. J Biol Chem 270: 18825-18830 (1995)
44. SAPERSTEIN DA, ROSENFELD PJ, BRESSLER NM, ROSA RH, JR., SICKENBERG M, STERNBERG P, JR., AABERG TM, SR., AABERG TM, JR., REAVES TA: Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology 109: 1499-1505 (2002)
45. SCHMIDT-ERFURTH U, HASAN T: Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 45: 195-214 (2000)
46. SCHMIDT-ERFURTH U, MICHELS S, BARBAZETTO I, LAQUA H: Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci 43: 830-841 (2002)
47. SCHMIDT-ERFURTH UM, KUSSEROW C, BARBAZETTO IA, LAQUA H: Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 109: 1256-1266 (2002)
48. SCHMIDT-ERFURTH UM, MICHELS S, KUSSEROW C, JURKLIES B, AUGUSTIN AJ: Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology 109: 2284-2294 (2002)
49. SHABAN H, RICHTER C: A2E and blue light in the retina: the paradigm of age-related macular degeneration. Biol Chem 383: 537-545 (2002)
50. SHVEDOVA AA, ALEKSEEVA OM, KULIEV I, MURANOV KO, KOZLOV YU P, KAGAN VE: Damage of photoreceptor membrane lipids and proteins induced by photosensitized generation of singlet oxygen. Curr Eye Res 2: 683-689 (1982)
51. SICKENBERG M: Early detection, diagnosis and management of choroidal neovascularization in age-related macular degeneration: the role of ophthalmologists. Ophthalmologica 215: 247-253 (2001)
52. SICKENBERG M: Photodynamic therapy (PDT) for choroidal neovascularization. Seminars in Ophthalmology 16: 177-239 (2002)
53. SICKENBERG M, BALLINI JP, VAN DEN BERG H: Photothérapie dynamique à la Visudyne et occlusion du vaisseau afférent: rationnel d'ine association synergique et options cliniques illustrées. J Soc Fr Opht accepted (2002)
54. SLAKTER J, GOLDBERG MF, GUYER DR, PEYMAN GA: Pipeline is bursting with new drugs aimed at AMD. Eye-World 7 (Nov): 5-8 (2002)
55. SPAIDE RF, DONSOFF I, LAM DL, YANNUZZI LA, JAMPOL LM, SLAKTER J, SORENSON J, FREUND KB: Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina 22: 529-535 (2002)
56. SPAIDE RF, FREUND KB, SLAKTER J, SORENSON J, YANNUZZI LA, FISHER Y: Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina 22: 545-549 (2002)
57. SPAIDE RF, MARTIN ML, SLAKTER J, YANNUZZI LA, SORENSON J, GUYER DR, FREUND KB: Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophthalmol 134: 62-68 (2002)
58. STAURENGHI G, MUSICCO I, SALVETTI P, VIOLA F: Combining photodynamic therapy and feeder vessel photocoagulation: a pilot study. Seminars in Ophthalmology 16: 233-236 (2002)
59. TAEUBER CM: Sixty-five Plus in America, in Current Population Reports, Census Bot (Ed.). U.S. Department of Commerce, Washington, D.C. 23-179 (1992)
60. TAP & VIP Study Groups: Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22: 6-18 (2002)
61. TAP Study Group: Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4. Retina 22: 536-544 (2002)
62. TAP Study Group: Photodynamic Therapy of Subfoveal Choroidal Neovascularisation in Age-Related Macular Degeneration With Verteporfin. One-Year Results of 2 Randomized Clinical Trials. TAP Report 1. Arch Ophthalmol 117: 1329-1345 (1999)
63. TAP Study Group: Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration With Verteporfin: Two-Year Results of 2 Randomized Clinical Trials. TAP Report 2. Arch Ophthalmol 119: 198-207 (2001)
64. TAP Study Group: Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration. Three-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials. TAP Report 5. Arch Ophthalmol 120: 1307-1314 (2002)
65. TAP Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes. TAP Report No. 3. Arch Ophthalmol 120: 1443-1454 (2002)
66. VAN DEN BERGH H: Photodynamic Therapy of Age Related Macular Degeneration: History and Principles. Seminars in Ophthalmology 16: 181-200 (2002)
67. VAN DEN BERGH H, BALLINI JP: Photodynamic Therapy for Age Related Macular Degeneration: Fundamentals, the Present Situation, and Future Developments, in Photodynamic Therapy of Ocular Diseases, Gragoudas ES, Miller J, Zographos L (Eds.). Lippincott William and Williams. 1-27 (2002)
68. VAN DEN BERGH H, BALLINI JP: Photodynamic Therapy: Basic Principles and Mechanisms, in Lasers in Ophthalmology - Surgical and Diagnostic Aspects, Fankhauser F, Kwasniewska S (Eds.). Kugler, The Hague. 1-23 (2002)
69. VAN DEN BERGH H, BALLINI JP, SICKENBERG M: On the selectivity of photodynamic therapy of choroidal neovascularisation associated with age-related macular degeneration. J Soc Fr Opht accepted (2002)
70. VAN KUIJK FJ, BUCK P: Fatty acid composition of the human macula and peripheral retina. Invest Ophthalmol Vis Sci 33: 3493-3496 (1992)
71. VINGERLING JR, KLAVER CC, HOFMAN A, DE JONG PT: Epidemiology of age-related maculopathy. Epidemiol Rev 17: 347-360 (1995)
72. VIP Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 108: 841-852 (2001)
73. VIP Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131: 541-560 (2001)
74. WANG LK, KANSAL S, PULIDO JS: Photodynamic therapy for the treatment of choroidal neovascularization secondary to rubella retinopathy. Am J Ophthalmol 134: 790-792 (2002)
75. WIHLMARK U, WRIGSTAD A, ROBERG K, NILSSON SE, BRUNK UT: Lipofuscin accumulation in cultured retinal pigment epithelial cells causes enhanced sensitivity to blue light irradiation. Free Radic Biol Med 22: 1229-1234 (1997)
76. WOODBURN KW, ENGELMAN CJ, BLUMENKRANZ MS: Photodynamic therapy for choroidal neovascularization: a review. Retina 22: 391-405; quiz 527-398 (2002)
77. YAMADA M, KAWAI M, KAWAI Y, MASHIMA Y: The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res 19: 300-304 (1999)
78. YOUNG RW: Pathophysiology of age-related macular degeneration. Surv Ophthalmol 31: 291-306 (1987)
79. YOUNG RW: Solar radiation and age-related macular degeneration. Surv Ophthalmol 32: 252-269 (1988)